Type/Product Area

Terms/Details (Date)

Abgenix Inc.

Genentech Inc. (NYSE:DNA)

Genentech exercised its option to extend for three years a licensing agreement for antibody- eneration technology

Genentech purchased Abgenix stock, and would pay milestone and royalty fees as products advance; the deal covering Xeno- Mouse technology originally was signed in 1999 (3/14)

(unit of Rigaku/

Serenex Inc.*

Deal for the co-crystallization of Serenex molecules with proteins expressed by ActiveSight

Additional details of the deal were not disclosed (2/23)

Aerogen Inc.

Biota Holdings Ltd. (Australia; ASX:BTA)

Deal to develop Biota's CS- 958, a long-acting neuraminidase inhibitor, with Aerogen's Aeroneb nebulizer

Work on the influenza product is being funded under a $5.6M grant to Biota from the National Institutes of Health; terms were not disclosed (3/9)


Dyadic International Inc. (OTC BB:DYAD)

Agencourt will sequence the genome of Dyadic's fungus, Chrysosporium lucknowense, also known as C1

The information will be used for potential new protein and enzyme products; terms of the deal were not disclosed (2/17)


Benitec Ltd. (Australia; ASX:BLT)

Benitec and its licensees got an option to nonexclusively license Alnylam-controlled IP in the field of expressed RNA interference

Alnylam would receive license fees and be entitled to milestone royalty payments on covered products; it also got reciprocal options on Benitec IP for expressed RNAi and synthetic siRNAs (4/12)

Ambion Inc.*

Cepheid Inc. (CEPH)

Cepheid got nonexclusive rights to incorporate Armored RNA technology in its in vitro molecular diagnostic products

The Ambion Diagnostics division will manufacture custom reagents for Cepheid; terms of the deal were not disclosed (4/11)

Amrad Corp.

Serologicals Corp. (SERO)

Serologicals subsidiary Chemicon International got additional rights to develop embryonic stem cell products into more kits and products

The expanded deal also included the Walter Eliza Hall Institute of Medical Research; the initial 1999 license covering leukemia inhibitory factor now includes non-therapeutic uses; terms were not disclosed (4/5)


Bionaut Pharmaceuticals Inc.*

Collaboration to identify anti- cancer compounds that inhibit the ability of tumor cells to survive stress conditions

Bionaut will provide and validate compounds that have shown activity; Analyti-Con will optimize them for further preclinical development by Bionaut; terms of the deal were not disclosed (4/14)

(Canada; ANPI)

CABG Medical Inc. (CABG)

CABG got a license to paclitaxel technology for treating restenosis and proliferative disease

Angiotech gets a warrant to purchase 1.26M CABG shares, exercisable at $0.01, and potential milestone and royalty payments; also, Angiotech will purchase up to $10M in CABG stock at a 15% premium (3/23)

Ardais Corp.*

Cytomyx Holdings plc* (UK)

Cytomyx is acquiring Ardais' biorepository of more than 130,000 clinically annotated biospecimens

Cytomyx also will acquire the lab facilities and equipment, and will hire Ardais' biological operations personnel; terms were not disclosed (3/30)

BioPharma Inc.

Genentech Inc. (NYSE:DNA)

They expanded collaboration to develop small-molecule drugs against an additional protein target in oncology

Array gets additional research funding, as well as potential milestone and royalty payments; the January 2004 deal covered two Array oncology programs; Genentech has rights to resulting products (4/7)

Avidex Ltd.*

Active Biotech AB (Sweden; SSE:ACTI)

Active will use Avidex's monoclonal T-cell receptor technology to help develop the cancer product Anyara

Avidex's mTCR product will be used for characterization of the drug during clinical development; terms were not disclosed (3/7)

BCY Life-
Sciences Inc.
(Canada; TSE:BSY)

Align Pharmaceuticals Inc.*

Align will further develop and market BCY's DCF 987, a Phase II product for respiratory conditions

BCY is entitled to up-front, milestone and royalty payments; the product is the first in Align's portfolio (2/25)

Benitec Ltd.
(Australia; ASX:BLT)

GenOway SA* (France)

GenOway got rights to develop transgenic animals using DNA-directed RNA interference

Benitec gets an up-front license fee and ongoing royalties under the worldwide, non-exclusive deal (3/22)

BioFocus plc

Senexis Ltd.* (UK)

Deal to accelerate lead discovery of Senexis drugs for Alzheimer's disease

Terms of the deal were not disclosed (3/7)

Caliper Life
Sciences Inc.

Amphora Discovery Corp.*

Amphora agreed to purchase a certain amount of LabChip products over two years

Terms of the deal were not disclosed (4/14)



Collaboration for the joint development of therapeutic antibodies for treating cancer

Caprion gets an up-front payment and license fees; the deal includes reciprocal milestone and royalty payments; also, ICOS has an option to co-develop and co-promote certain products (3/31)

Celgene Corp.

EntreMed Inc. (ENMD)

EntreMed licensed rights to Celgene's small-molecule tubulin inhibitor compounds for the treatment of cancer

Celgene gets an up-front licensing fee and potential milestone payments under the worldwide, exclusive deal (3/24)


Tripos Inc. (TRPS)

They entered a new deal to continue a collaboration to advance discovery of COMT inhibitors

They already have identified series of compounds active against the target catechol-O-methyltransferase; now they will optimize those compounds (4/14)


Dendreon Corp. (DNDN)

They expanded and extended deal under which ChemDiv supplies chemistry services to Dendreon

The services support Dendreon's discovery programs for targeted cancer therapies; terms of the deal were not disclosed (4/1)

Chicago Labs

Spectrum Pharmaceuticals Inc. (SPPI)

Spectrum acquired an exclusive license to endothelin B agonists for the treatment of cancer

Chicago Labs, which licensed the technology from the University of Illinois, gets $100,000 up front, along with potential milestone and royalty payments (2/18)


Benitec Ltd. (Australia; ASX:BLT)

Benitec got a nonexclusive license to use pools of siRNAs against viral diseases, and a coexclusive sublicense to two sequences targeting HIV genes

In return, CombiMatrix got a nonexclusive license to patents for the development of RNAi therapeutics against diseases resulting from biological, chemical, radioactive and other weapons; the companies also will collaborate in other areas (2/22)

Corixa Corp.

Panbio Ltd. (Australia; ASX:PBO)

Panbio acquired technology to help in the development of assays for the diagnosis of two tick-borne diseases

Corixa gets an up-front payment, annual maintenance payments and royalties on any resulting product sales (4/12)

Corixa Corp.

Lorantis Ltd.* (UK)

Deal to continue development of a hepatitis B vaccine containing Corixa's RC-529 adjuvant and Lorantis' CV-1831, a hepatitis B core antigen

The antigen previously was owned by Apovia Inc.; Lorantis acquired Apovia's interest in the technology and will assume many of Apovia's responsibilities under the deal with Corixa; Lorantis and Corixa will share costs and revenues (3/3)

Invest AB*

DiObex Inc.*

DiObex licensed worldwide rights to inhibitors of cortisol synthesis

The technology has applications in metabolic diseases; terms of the deal were not disclosed (4/11)


Pharmagene plc (UK; LSE: PGN)

Cresset will attempt to find novel leads against a Pharmagene discovery target

Terms of the deal were not disclosed (3/2)

Crucell NV
(the Netherlands;

Vascular Biogenics Ltd.* (Israel)

Vascular Biogenics got rights to use the PER.C6 cell line in gene therapeutics based on adenoviral vectors

Crucell gets a research license payment and annual license fees in the nonexclusive deal (3/30)

Crucell NV
(the Netherlands;

SingVax Pte. Ltd. (Singapore)

SingVax got rights to PER.C6 technology for use in vaccines against Japanese encephalitis

Crucell gets up-front, annual and potential milestone payments, as well as royalties on any sales and a preferred position to negotiate marketing rights outside the Asia- Pacific region (3/22)

Curis Inc.

Genentech Inc. (NYSE:DNA)

Collaboration to develop small- molecule modulators of an undisclosed pathway involved in cell proliferation; the pathway is a regulator of tissue formation and repair

Curis gets an up-front license fee of $3M and up to $6M more over two years in research support; Curis also could get milestone and royalty payments; the deal, excluding royalties, could be worth $140M to Curis if two products are developed in two indications each; Curis also retains certain rights (4/4)


Medarex Inc. (MEDX)

They expanded the scope of a November 2002 deal focused on drug targets for immunological diseases to include targets in other areas of interest

Cytos gets an up-front payment, and can earn license fees, milestones and royalties; Medarex gets exclusive rights for monoclonal antibodies against the targets, and the first right of negotiation for use of the targets in small- olecule drug discovery and as protein therapeutics (4/1)

Demegen Inc.*

Pacgen Bio- pharmaceuticals Corp.* (Canada)

Pacgen got a license to certain peptides for treating oral diseases

Pacgen's initial focus will be on a treatment for oral candidiasis; terms of the deal were not disclosed (3/22)


TolerRx Inc.*

TolerRx acquired rights to the therapeutic use of anti- CD3 antibodies in autoimmune diseases

TolerRx also got rights to a panel of fully human anti-CD3 antibodies under a licensing agreement between Diabetogen and Abgenix Inc.; terms of the deal were not disclosed (4/4)

Directif GmbH
subsidiary of
November AG*)

Epidauros Biotechnologie AG* (Germany)

They formed a joint venture to develop applications for Directif's LabChip technology in personalized medicine

They are pooling know-how to develop applications for drug development; terms were not disclosed (3/23)


Chroma Therapeutics Ltd.* (UK)

DPI will use its compound collection and other technologies to identify compounds for Chroma targets

Terms of the deal were not disclosed (3/29)

Domantis Ltd.*

Tanox Inc. (TNOX)

Domantis will use its Domain Antibodies technology to discover therapeutic product leads for Tanox

Domantis gets an up-front fee, research funding and annual fees, as well as potential milestone and royalty payments; the focus is autoimmune diseases (3/22)

Durect Corp.

Endo Pharmaceuticals Inc. (ENDP)

Endo got exclusive rights to Durect's sufentanil-containing transdermal patch in the U.S. and Canada

Durect gets $10M up front and up to $35M in regulatory and commercial milestones, as well as royalties on any sales of the pain product; Endo assumed development responsibilities (3/14)


QuatRx Pharmaceuticals Co.*

QuatRx acquired rights to QRX-431, an orally active compound for the treatment of lipid disorders and obesity

Terms of the exclusive worldwide deal were not disclosed (3/15)

Enlyton Ltd.*

Neoprobe Corp. (OTC BB:NEOP)

Neoprobe licensed two patents that are related to its RIGS technology

The deal provides Neoprobe with an extension of methodology patent protection for the technology; terms were not disclosed (4/5)


BioLineRx Ltd.* (Israel)

BioLineRx licensed worldwide rights to BL- 060, a small molecule for treating fatty liver disease

Terms of the exclusive deal on the preclinical product were not disclosed (3/14)


ParAllele BioScience Inc.*

License and co-marketing agreement to provide genetic screening technology and services

ParAllele is licensing more than 400 SNPs from Genaissance, and combining them with certain public-domain SNPs in an assay panel; Genaissance will be the first company to offer the panel for research uses (4/6)

Geron Corp.

Exeter Life Sciences Inc.*

They formed a new company named stART Licensing Inc. for licensing animal cloning technologies

The portfolio includes nuclear transfer cloning technology developed at the Roslin Institute; Exeter will provide additional capital for the effort, and own 50.1% of the company; Geron also can get up-front and milestone payments (4/6)

HTS Biosystems

Biacore International AB (Sweden; SSE:BCOR)

Biacore acquired the FLEXChip System and related assets from HTS

Biacore is paying $4M for the technology used in protein-interaction analysis (3/10)

Icoria Inc.

Admet Technologies Inc.*

Icoria will characterize Admet's human adult hepatocytes to improve their value as a predictive toxicology screening tool

Admet will use the information to identify cells that could be used in toxicology assays; Icoria retains rights to develop any resulting novel diagnostic biomarkers (4/19)


Plexxikon Inc.*

Invitrogen will provide kinase screening services on Plexxikon kinase inhibitor libraries

Plexxikon intends to develop drugs for oncology, inflammation and other diseases; terms of the service agreement were not disclosed (4/6)

IriSys Inc.*

Avanir Pharmaceuticals Inc. (AMEX:AVN)

Avanir acquired additional rights to its late- stage CNS product Neurodex

Avanir licensed the product from IriSys in 2000; it has no further obligation to IriSys after paying $1.925M in cash and 2M shares of stock; Avanir still has royalty and other obligations to the discoverer, The Center for Neurologic Study (3/9)


OncoGenex Technologies Inc.*

They broadened collaboration to allow for development of two additional second- eneration antisense cancer drugs

Isis gets an up-front fee along with potential milestone and royalty payments; two drugs already are being developed under the deal that started in 2001 (3/16)

Large Scale
Biology Corp.

Icon Genetics AG* (Germany)

Deal to combine technologies to develop an undisclosed product

They will pool their plant-based platforms in an attempt to develop the difficult-to- produce drug; terms were not disclosed (3/1)


Jerini AG* (Germany)

Co-marketing deal between MorphoSys division Antibodies by Design and Jerini subsidiary JPT Peptide Technologies GmbH

They will co-market monoclonal antibodies generated by Antibodies by Design and the complementary peptide-based services and products from JPT; each will offer the services of the other (4/18)


Amgen Inc. (AMGN)

Morphotek will apply its technology to Amgen cell lines to develop high-titer antibody-producing cell lines

Morphotek gets research payments and is entitled to milestone payments in the deal, which is focused on producing cell lines for scalable manufacturing (4/18)

Mutabilis SA* (France)

Chiron Corp.

Chiron Vaccines licensed rights to use Mutabilis technology in development of a prophylactic vaccine

Mutabilis is entitled to license fees, milestone payments and royalties on any sales; the target was not disclosed (4/11)

Nanogen Inc.

DeCode Genetics Inc. (Iceland; DCGN)

Nanogen will provide a new genomics assay for single nucleotide polymorphism discovery and screening

Terms of the supply and license agreement were not disclosed (4/18)

NascaCell IP

Discovery Partners International Inc. (DPII)

Deal to jointly provide aptamer-based drug discovery services to the life sciences industry

The effort combines NascaCell's expertise in aptamers with DPI's drug discovery capabilities; terms were not disclosed (3/21)


Metabolic Pharmaceuticals Ltd. (Australia; ASX:MBP)

Deal to co-develop Neuren's neuroregenerative peptides for treating degenerative conditions

They will jointly develop the technology and equally share all intellectual property and commercial outcomes (3/4)


Nanogen Inc. (NGEN)

Deal under which Nanogen will develop diagnostics that detect genetic variations associated with responses to depression and psychosis drugs

Terms of the nonexclusive, worldwide license agreement were not disclosed (3/22)

Drug Discovery

CV Therapeutics Inc. (CVTX)

Drug discovery deal under which Pharmacopeia will provide discovery technologies

Pharmacopeia gets research funding in addition to potential milestone and royalty payments (3/23)


Vernalis plc (UK; VNLS)

Vernalis acquired rights and other assets related to the oncology target Pin1

Pintex gets an initial cash payment, and would get up to 1.5M Vernalis shares should a drug candidate enter human trials, which is not expected before 2008; Pintex would get another payment, bringing the total to $6.5M, upon product approval (3/31)


Innovate Oncology Inc. (OTC BB:IOVO)

Innovate acquired rights to capridine-beta, a nitroacridine derivative, for treating prostate cancer

Phase I trials for the drug are being planned; terms of the deal were not disclosed (4/8)

Protein Design
Labs Inc.

Seattle Genetics Inc. (SGEN)

Seattle Genetics got exclusive rights to PDL's anti-CD33 program for both unconjugated antibody and antibody-drug conjugate applications

PDL gets an up-front fee and is entitled to milestone and royalty payments; the pre-clinical program has applications in cancer; also, royalties payable by PDL under an existing collaboration were reduced (4/13)

Protein Polymer

Genencor International Inc. (GCOR)

They expanded 2000 deal to include personal care product applications

Genencor already had rights to industrial applications of PPTI's polymer technology; PPTI gets an up-front and annual payments, as well as royalties on any sales (3/30)


Viropro Inc. (Canada; OTC BB:VPRO)

Deal to commercialize recombinant biogeneric therapeutics for international markets

They intend to evaluate and scale up certain biotherapeutic proteins, then transfer candidates to international clients for local commercial manufacturing (3/15)

QLT Inc.
(Canada; QLTI)

VasoGenix Pharmaceuticals Inc.*

Deal to develop a sustained- release formulation of Vaso-Genix's calcitonin gene- related peptide

QLT will develop the delivery system for CGRP; VasoGenix has the option to acquire an exclusive worldwide royalty-bearing license to the product (4/11)

Quadrant Drug
Delivery Ltd.*

CoTherix Inc. (CTRX)

Deal to develop an extended-release formulation of CoTherix's Ventavis

The product is approved for treating pulmonary arterial hypertension; terms of the deal were not disclosed (4/5)

ReOx Ltd.*

Unnamed U.S.- based company

Deal to co-develop drugs targeting cellular oxygen regulation through the transcription factor hypoxia inducible factor

ReOx is getting $9M up front and is entitled to research funding, milestone payments and royalties on any resulting sales; the research has applicability in a number of diseases (4/18)


Rexahn Corp.*

Rexahn licensed technology similar to antibiotics with activity against central nervous system activity

The lead compound, RX-10,100, is expected to enter clinical trials within a year; terms of the deal were not disclosed (3/3)


TissueGene Inc.*

Research and license agreement to develop regulated cell therapy treatments for bone restoration and repair

The effort will combine TissueGene's cell therapy technology and RheoGene's Rheo-Switch Therapeutic System to develop non- surgical treatments for non-union bone fractures, bone wounds and osteoporosis (4/19)

Scynexis Inc.*

Adherex Technologies Inc. (AMEX:ADH)

Scynexis will provide medicinal and analytical chemistry services to Adherex

The work will focus on Adherex's small- molecule cadherin antagonist development programs; terms were not disclosed (3/23)


OncoMethylome Sciences SA* (Belgium)

OMS licensed fluorescent detection technology for development of diagnostic assays for detecting DNA methylation patterns

OMS made the deal on the Amplifluor technology with Serologicals subsidiary Chemicon International Inc.; terms of the deal were not disclosed (3/30)


Inncardio Inc. (OTC BB:INDO)

Deal to develop new formulations of established drugs using Sigmoid's delivery and formulation technology

Neither the drugs nor the terms of the deal were disclosed (4/18)

Sunol Molecular Corp.*

Tanox Inc. (TNOX)

Tanox is acquiring Sunol's tissue factor antagonist program for treating inflammatory diseases and cancer

Tanox will issue 800,000 shares of common stock, which were valued at $8.26M, and pay $6 million to Sunol in the deal; Tanox also got nonexclusive rights to certain technologies for protein and antibody expression (3/28)


Serono SA (Switzerland; NYSE:SRA)

Serono licensed exclusive rights to Transceptor and Synfusion technologies for developing interferon-beta:Fc products

Serono intends to develop an inhaled interferon-beta therapy for multiple sclerosis; Syntonix gets an up-front license fee and is eligible for development milestones and sales royalties (3/31)

VASTox plc

Undisclosed company

VASTox will target drugs to specific organs and cell types through the use of sugars

VASTox will perform the work under a nine-month fee-for-service deal with the unnamed European company (2/23)

ViaCell Inc.

Genzyme Corp. (GENZ)

Collaboration related to use of islet stem cells for treating diabetes

The companies will conduct preclinical research in the area; terms of the deal were not disclosed (3/15)


NascaCell IP GmbH* (Germany) and PSF Biotech AG* (Germany)

The three companies formed a consortium to identify and develop new drugs for the inhibition of tumor angiogenesis

The collaboration, using an aptamer-based approach, will integrate the technology platforms of the three companies; the PADDION consortium will receive initial funding from the BioChancePlus program of the German Federal Ministry of Education and Research (4/13)


* Private companies are indicated with an asterisk.

Unless otherwise notes, the trading symbols listed for public biotechnology companies are on the Nasdaq market.

AIM = Alternative Investment Market; AMEX = American Stock Exchange; ASX = Australian Stock Exchange; FSE = Frankfurt Stock Exchange; LSE = London Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; SSE = Stockholm Stock Exchange; SWX = Swiss Stock Exchange; TSE = Toronto Stock Exchange.